ReviewImmunoTargets and therapy2013
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities.
Review in ImmunoTargets and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- YBX1 orchestrates LDHA-mediated metabolic reprogramming and NF-κB activation to drive clear cell renal cell carcinoma progression.Cell death & disease · 2026Article
- Revisiting Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Evidence of Survival Benefit with First-Line Immunotherapy and Targeted Therapy Regimens.Journal of clinical medicine · 2025Article
- A case report of metastatic renal cell carcinoma and ANCA associated vasculitis.BMC nephrology · 2025Article
- Metastatic Clear Renal Cell Carcinoma in Urinary Bladder at Presentation-A Rare Incidental Case Report and Literature Review.Clinical case reports · 2025Article
- Predictive Factors and the Role of Conventionally Fractionated Radiation Therapy for Bone Metastasis from Renal Cell Carcinoma in the Era of Targeted Therapy.Medicina (Kaunas, Lithuania) · 2024Article
- Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England.Drugs - real world outcomes · 2024Article
- Characterization ofCancers · 2024Article
- Long non-coding RNAs: regulators of autophagy and potential biomarkers in therapy resistance and urological cancers.Frontiers in pharmacology · 2024Review
- Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma.Frontiers in oncology · 2024Article
- CD15 Is a Risk Predictor and a Novel Target in Clear Cell Renal Cell Carcinoma.Pathobiology : journal of immunopathology, molecular and cellular biology · 2024Article
- Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.Medical sciences (Basel, Switzerland) · 2023Review
- Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea.Applied health economics and health policy · 2021Article
- Efficacy and safety of anti-vascular endothelial growth factor therapies in older patients for first line treatment of metastatic renal cell carcinoma.Translational andrology and urology · 2021Article
- Metabolomic and elemental profiling of human tissue in kidney cancer.Metabolomics : Official journal of the Metabolomic Society · 2021Article
- Nuclear magnetic resonance and surface-assisted laser desorption/ionization mass spectrometry-based serum metabolomics of kidney cancer.Analytical and bioanalytical chemistry · 2020Article
- Observational
- Expression of RSK4, CD44 and MMP-9 is upregulated and positively correlated in metastatic ccRCC.Diagnostic pathology · 2020Article
- Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment.World journal of urology · 2019Article
- Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.Drugs & aging · 2019Review
- Extracellular Vesicles and Carried miRNAs in the Progression of Renal Cell Carcinoma.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of advanced renal cell carcinoma (RCC) remains a major therapeutic challenge for clinicians. Despite advances in the understanding of the immunobiology of RCC and the availability of several novel targeted agents, there has been little improvement in the survival of patients with metastatic RCC. This review will focus on the recent understanding of risk factors and treatment options and outcomes of metastatic RCC, in particular, targeted therapeutic agents that inhibit vascular endothelial growth factor and mammalian target of rapamycin pathways. Prospective studies are required to determine whether sequential targeted therapy will further improve progression-free survival in RCC. Ongoing research to develop novel agents with better tolerability and enhanced efficacy in the treatment of metastatic RCC is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.